ENOPH1 Activators
ENOPH1 activators encompass a range of chemical compounds that can enhance the functional activity of ENOPH1 through their influence on various cellular processes. Microtubule-disrupting agents such as vinblastine, nocodazole, and colchicine, and the microtubule-stabilizing agent taxol, perturb microtubule dynamics. This disruption or stabilization of microtubules can trigger a compensatory response in ENOPH1, leading to an increase in its functional activity to restore or maintain nuclear pore complex formation.
Proteasome inhibitors like epoxomicin, bortezomib, and MG132, along with the protease inhibitor actinonin, inhibit protein degradation mechanisms, leading to protein accumulation within the cell. This increased protein load can necessitate an increase in nuclear pore complex formation, thus enhancing the functional activity of ENOPH1. Similarly, inhibitors of nuclear export and protein trafficking from the endoplasmic reticulum, such as leptomycin B and brefeldin A respectively, can increase the demand for nuclear pore complex formation, thereby enhancing ENOPH1 function. Compounds that inhibit N-linked glycosylation and sarcoplasmic/endoplasmic reticulum Ca2+ ATPase, like tunicamycin and thapsigargin, disrupt cellular processes and induce stress responses. Tunicamycin's inhibition of N-linked glycosylation leads to glycoprotein accumulation, which increases the need for nuclear pore complexes to facilitate their transport, thus indirectly stimulating ENOPH1 function. Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase. This disruption necessitates an increase in nuclear pore complex formation to maintain cellular equilibrium, thereby enhancing the functional activity of ENOPH1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine, a microtubule-disrupting agent, perturbs microtubule dynamics, which can trigger a compensatory response in ENOPH1, leading to an increase in its functional activity to restore or maintain nuclear pore complex formation. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole, another microtubule-disrupting agent, distorts microtubule dynamics, thereby provoking a compensatory response in ENOPH1. This results in escalated ENOPH1 activity to restore nuclear pore complex formation. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine, a potent microtubule-disrupting agent, can stimulate the functional activity of ENOPH1 by disrupting microtubule dynamics, which leads to a compensatory response in ENOPH1 for restoring nuclear pore complex formation. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Taxol, a microtubule-stabilizing agent, can stabilize microtubules which, in turn, triggers a compensatory response in ENOPH1, leading to an increase in its functional activity to maintain nuclear pore complex formation. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin, a proteasome inhibitor, prevents protein degradation, leading to protein accumulation within the cell. This increase in protein load necessitates an increase in nuclear pore complex formation, thus enhancing the functional activity of ENOPH1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, another proteasome inhibitor, inhibits protein degradation mechanisms, leading to protein accumulation. This increased protein load demands an increase in nuclear pore complex formation, thereby enhancing ENOPH1 function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132, a proteasome inhibitor, impedes protein degradation, leading to accumulation of protein within the cell. This process necessitates an increase in nuclear pore complex formation, thereby enhancing ENOPH1 function. | ||||||
Actinonin | 13434-13-4 | sc-201289 sc-201289B | 5 mg 10 mg | $170.00 $385.00 | 3 | |
Actinonin, a protease inhibitor, inhibits protein degradation mechanisms, leading to accumulation of protein within the cell. This increase in protein load increases the demand for nuclear pore complex formation, thereby enhancing the functional activity of ENOPH1. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B, an inhibitor of nuclear export, can increase the demand for nuclear pore complex formation, thereby enhancing ENOPH1 function. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits protein trafficking from the endoplasmic reticulum, increasing the demand for nuclear pore complex formation, thereby enhancing ENOPH1 function. | ||||||